Provided by Tiger Fintech (Singapore) Pte. Ltd.

INmune Bio Inc

7.86
+0.01000.13%
Post-market: 7.880.0200+0.25%17:06 EDT
Volume:166.96K
Turnover:1.32M
Market Cap:180.23M
PE:-3.73
High:8.00
Open:7.76
Low:7.65
Close:7.85
Loading ...

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

GlobeNewswire
·
16 Apr

INmune Bio partners with Cell, Gene Therapy Catapult to scale up CORDStrom

TIPRANKS
·
14 Apr

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

GlobeNewswire
·
14 Apr

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

GlobeNewswire
·
01 Apr

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com
·
28 Mar

INmune Bio Q4 EPS $(0.40) Beats $(0.53) Estimate

Benzinga
·
28 Mar

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

THOMSON REUTERS
·
28 Mar

Press Release: INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Dow Jones
·
28 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

INmune Bio Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
25 Mar

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

THOMSON REUTERS
·
24 Mar

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

GlobeNewswire
·
24 Mar

Inmune Bio (INMB) Receives a Buy from Scotiabank

TIPRANKS
·
05 Mar

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Simply Wall St.
·
27 Feb

INmune Bio Is Maintained at Buy by Maxim Group

Dow Jones
·
14 Feb

INmune Bio Opens Phase Ii in High Dose Cohort of Inkmune™ Trial in Prostate Cancer

THOMSON REUTERS
·
12 Feb

INmune Bio Inc - Phase 1 Cohorts Show No Safety Issues

THOMSON REUTERS
·
12 Feb

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

GlobeNewswire
·
12 Feb

INmune Bio Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
11 Feb

INmune Bio price target raised to $23 from $22 at Scotiabank

TIPRANKS
·
11 Feb